# US Blood Transfusion Diagnostics Market

> US Blood Transfusion Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (Infectious Disease Testing, Blood Grouping Tests, Compatibility Testing, Nucleic Acid Testing), By Technique (Enzyme-Linked Immunosorbent Assay, Polymerase Chain Reaction, Chemiluminescent Immunoassay, Microbiological Techniques), By End Users (Hospitals, Blood Banks, Diagnostic Laboratories, Academic Institutions) and By Applications (Transfusion Medicine, Organ Transplantation, Clinical Research) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.89%
- **2024:** $ 2,295.16 Million
- **2025:** $ 2,430.34 Million
- **2035:** $ 4,308.57 Million
- **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Grifols (ES), Terumo Corporation (JP), Baxter International (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Hologic (US)

**Report ID:** MRFR/LS/17162-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-blood-transfusion-diagnostics-market-18690

---

## Market Summary

## **US Blood Transfusion Diagnostics Market Overview**

As per MRFR analysis, the **US Blood Transfusion Diagnostics Market Size** was estimated at **1.07 (USD Billion) in 2023**. The US Blood Transfusion Diagnostics Market Industry is expected to grow from **1.1 (USD Billion) in 2024** to **1.65 (USD Billion) by 2035**. The US Blood Transfusion Diagnostics Market CAGR (growth rate) is expected to be around **3.754%** during the forecast period (2025 - 2035).

### **Key US Blood Transfusion Diagnostics Market Trends Highlighted**

The US Blood Transfusion Diagnostics Market is seeing significant momentum driven by the rising demand for safe and effective blood transfusions. This is largely due to the increasing incidence of blood disorders, surgical procedures, and emergency medical situations. Key market drivers include stringent regulations and quality standards imposed by authorities like the **Food and Drug Administration (FDA)** and the **Centers for Disease Control and Prevention (CDC)**, which ensure the safety and efficacy of blood supplies. As these regulations evolve, they encourage the adoption of advanced diagnostic technologies and processes to enhance blood testing accuracy.

Opportunities also exist in the development of innovative testing solutions, particularly in molecular diagnostics. The growing emphasis on personalized medicine offers a potential area for expansion, as healthcare providers seek better methods to match donors and recipients to minimize transfusion-related complications. Additionally, the incorporation of automation in blood screening processes presents avenues for efficiency, improving turnaround times and reducing human error. Recent trends in the US indicate a shift towards integrating digital health technologies, such as telemedicine and data analytics, into blood transfusion diagnostics.

These advancements facilitate remote consultation and faster decision-making, proving critical in urgent healthcare settings. Moreover, the increased awareness regarding the importance of blood donation and its impact on public health further fuels growth in the sector. As hospitals and blood banks continue to strengthen their diagnostic capabilities, the industry is poised to expand in alignment with evolving healthcare dynamics and technological advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Blood Transfusion Diagnostics Market Drivers**

### **Increasing Awareness About Blood Safety and Screening**

The increasing awareness of blood safety and the need for screening has significantly advanced the US Blood Transfusion Diagnostics Market Industry. Blood transfusion procedures are critically important as they can mitigate the risks of transfusion-transmitted infections. Data from the **Centers for Disease Control and Prevention** indicate that around **13,000 individuals** in the United States are diagnosed with HIV annually, emphasizing the need for rigorous blood screening for infectious diseases. Organizations such as the **American Red Cross** advocate for better blood safety protocols and screening processes, significantly contributing to raised public awareness.

This push for safety and health directly correlates with enhancements in [blood transfusion diagnostics](../../../reports/blood-transfusion-diagnostics-market-1126) technologies, indicating that the market is forecasted to grow due to increased demand for safer transfusion practices. Additionally, regulatory bodies including the **Food and Drug Administration** have stringent guidelines, driving the necessity for advanced diagnostics solutions.

### **Rising Incidence of Blood-Related Disorders**

The rise in blood-related disorders, such as hemophilia and thalassemia, is a critical driver for the US Blood Transfusion Diagnostics Market Industry. According to the **National Hemophilia Foundation**, approximately **20,000 people** in the United States have hemophilia, a disorder that often requires regular blood transfusions. The increase in patients requiring blood products has propelled healthcare institutions to innovate and strengthen blood diagnostic services, contributing to market growth.

Moreover, organizations such as the **Thalassemia International Federation** play a role in raising awareness and facilitating better treatment plans, which in turn drives the need for efficient blood diagnostics. This heightened awareness of blood disorders elevates the demand for blood transfusion diagnostics, leading to sector growth.

### **Technological Advancements in Diagnostic Solutions**

Technological advancements in diagnostic solution innovation are propelling the US Blood Transfusion Diagnostics Market Industry forward. The integration of artificial intelligence and automated systems in laboratories has reduced processing times for blood tests significantly and improved accuracy. According to the **American Association of Blood Banks**, technological enhancements, including nucleic acid testing, have raised the sensitivity of pathogen detection in blood products, improving patient outcomes.

Entities like **Thermo Fisher Scientific**, known for their high-performance diagnostic products, are at the forefront of these innovations. The continuous development and introduction of new technologies support increased market reliability and foster demand, attracting investments from various stakeholders in the healthcare sector.

### **Government Initiatives and Funding for Blood Safety**

Government initiatives aimed at enhancing blood safety significantly influence the US Blood Transfusion Diagnostics Market Industry. Federal programs emphasizing enhanced blood testing and safety standards have led to improved healthcare practices. For example, the **National Institutes of Health** has allocated substantial funding towards blood safety research and initiatives, promoting the development of reliable diagnostic tools. Moreover, the US government's ongoing support for Research and Development in blood safety technologies creates a favorable environment for innovation.

As these programs promote advancements and support new diagnostic technologies, they indirectly boost the demand within the blood transfusion diagnostics arena, facilitating market expansion.

## **US Blood Transfusion Diagnostics Market Segment Insights**

### **Blood Transfusion Diagnostics Market Product Type Insights**

The US Blood Transfusion Diagnostics Market encompasses a diverse range of product types, which play a crucial role in ensuring safe blood transfusions across healthcare settings. A significant aspect of this market is Infectious Disease Testing, which is essential for detecting viral and bacterial pathogens in donated blood, thereby safeguarding recipients from transfusion-transmissible infections. This segment remains vital as regulatory bodies in the United States impose strict screening guidelines, ensuring that blood donations are rigorously tested. Another critical area is Blood Grouping Tests, which are fundamental in determining a patient's blood type, a prerequisite for any transfusion procedure.

The growing number of emergency medical services and surgical procedures accentuates the demand for efficient blood grouping testing methods, reinforcing its significance within the market.

Compatibility Testing is also a pivotal segment that ensures the transfusion of compatible blood products, reducing adverse reactions and enhancing transfusion outcomes. It involves crossmatching the donor’s and recipient’s blood to confirm compatibility, which is paramount in preventing potential complications. Nucleic Acid Testing offers a modern approach to enhancing blood safety by detecting viral genetic material at earlier stages post-infection, thereby significantly reducing the window period for certain infectious agents. This advanced testing method has gained traction due to growing concerns about blood safety and the increasing prevalence of infectious diseases.

Overall, the US Blood Transfusion Diagnostics Market remains robust, driven by advancements in technology and an unwavering commitment to patient safety, with each product type contributing uniquely to the overall efficiency and reliability of blood transfusion practices.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Blood Transfusion Diagnostics Market Technique Insights**

The Technique segment of the US Blood Transfusion Diagnostics Market plays a crucial role in ensuring the safety and compatibility of blood transfusions. As healthcare standards evolve, methodologies such as Enzyme-Linked Immunosorbent Assay (ELISA) are essential for their sensitivity and specificity in detecting antibodies and antigens relevant to transfusion safety. Polymerase Chain Reaction (PCR) stands out for its ability to identify viral and bacterial pathogens quickly, which enhances patient safety by minimizing the risks of transfusion-transmitted infections. Chemiluminescent Immunoassay offers significant advantages in speed and versatility, making it valuable in various settings where time-sensitive diagnostics are critical.

Microbiological Techniques remain foundational for assessing microbial safety in blood products and ensuring compliance with stringent regulations. The growth within these techniques is driven by advancements in technology and the increasing demand for reliable diagnostic solutions in blood transfusion practices. The US Blood Transfusion Diagnostics Market segmentation shows that these techniques are not only vital in augmenting patient outcomes but also in driving innovations that enhance the efficiency and reliability of transfusion processes across the healthcare sector.

### **Blood Transfusion Diagnostics Market End User Insights**

The US Blood Transfusion Diagnostics Market exhibits diverse applicability across various End User categories, including Hospitals, Blood Banks, Diagnostic Laboratories, and Academic Institutions, which play crucial roles in the healthcare ecosystem. Hospitals are significant consumers of blood transfusion diagnostics, as they ensure patient safety by detecting infectious diseases. Blood Banks serve as vital components for blood collection, processing, and storage, hence necessitating advanced diagnostic tools for efficiency and accuracy. Diagnostic Laboratories contribute as key players in analyzing blood types and screening for diseases, enhancing the reliability of transfusion outcomes.

Academic Institutions support the market by driving Research and Development initiatives, which refine existing technologies and develop novel diagnostic solutions. The integration of technological advancements, coupled with the rising demand for improved healthcare services, is expected to propel the growth across these segments. Factors such as increasing incidences of blood disorders and the necessity for safe blood transfusions are anticipated to further stimulate the market. Moreover, government initiatives aimed at enhancing blood safety and supporting blood banks and hospitals will significantly propel the US Blood Transfusion Diagnostics Market revenue.

### **Blood Transfusion Diagnostics Market Application Insights**

The Application segment of the US Blood Transfusion Diagnostics Market encompasses vital areas such as Transfusion Medicine, Organ Transplantation, and Clinical Research, contributing significantly to enhancing patient care and outcomes. Transfusion Medicine is crucial for ensuring safe blood transfusions and minimizing risks associated with incompatible blood types. This area is characterized by advances in screening techniques and the implementation of stringent safety protocols. Organ Transplantation relies heavily on accurate diagnostics for matching donors and recipients, which is essential for transplant success and reducing rejection rates.

Moreover, Clinical Research plays a pivotal role in driving innovation within the market, focusing on the development of advanced tools and methodologies to improve diagnostic accuracy. The market is influenced by growing demand for blood compatibility testing and the rise in organ transplant procedures, supported by governmental efforts to promote organ donation. Challenges such as regulatory compliances and the need for continuous improvement in diagnostic accuracy remain prominent. Overall, the diverse applications ensure that the US Blood Transfusion Diagnostics Market remains dynamic, with each application addressing crucial health needs, thereby underscoring its importance within the healthcare framework.

## **US Blood Transfusion Diagnostics Market Key Players and Competitive Insights**

The US Blood Transfusion Diagnostics Market is a critical component of healthcare, enabling the safe and effective management of blood transfusions through innovative diagnostic solutions. The market is characterized by its dynamic landscape, driven by advancements in technology, regulatory requirements, and an increasing focus on patient safety. The competitive insights reveal a diverse array of players ranging from established corporations to specialized entities, all aiming to enhance the accuracy, reliability, and efficiency of blood transfusion diagnostics.

This sector relies heavily on collaborations, research and development, and strategic partnerships to stay ahead of the curve in addressing the complex challenges of blood safety, disease screening, and compatibility testing. The continuous evolution of diagnostic technologies, including molecular testing and automation, plays a significant role in shaping competitive strategies, allowing companies to leverage their strengths and respond adeptly to changing market demands.

### **Siemens Healthineers**

Siemens Healthineers is a powerhouse in the US Blood Transfusion Diagnostics Market, recognized for its strong portfolio of diagnostic services and innovative technologies. The company has a robust market presence, primarily due to its commitment to research and development, leading to the release of cutting-edge products that streamline laboratory workflows and enhance diagnostic accuracy. Siemens Healthineers excels in integrating advanced automation and digitalization into its offerings, which significantly improves the efficiency of blood screening and transfusion processes.

In this competitive environment, the company's strengths include its expansive network of healthcare solutions, strong customer relationships, and extensive experience in developing integrated diagnostic systems. This positions Siemens Healthineers as a formidable competitor, helping healthcare institutions ensure patient safety while maintaining high operational standards.

### **Mayo Clinic Laboratories**

Mayo Clinic Laboratories stands out in the US Blood Transfusion Diagnostics Market through its commitment to quality and innovation. Known for its leadership in laboratory medicine, Mayo Clinic Laboratories offers a comprehensive range of services, including blood type testing, pathogen testing, and compatibility assessments, ensuring high standards in transfusion safety. The company's strength lies in its strong reputation for clinical excellence and its dedication to advancing diagnostic capabilities through continuous research and validation. Furthermore, Mayo Clinic Laboratories actively engages in strategic collaborations and partnerships to enhance its product offerings and expand its market reach.

Through mergers and acquisitions, the company has solidified its position, augmenting its service capabilities and broadening its expertise in blood diagnostics. This strategic focus aids in addressing the evolving needs of healthcare providers and patients alike, ensuring that the company remains at the forefront of the market.

### **Key Companies in the US Blood Transfusion Diagnostics Market Include**

## **US Blood Transfusion Diagnostics Market Industry Developments**

In recent months, the US Blood Transfusion Diagnostics Market has seen significant developments among key players. **Siemens Healthineers** continues to innovate with their high-performance analyzers, enhancing transfusion compatibility testing. **Mayo Clinic Laboratories** is advancing in genetic testing to ensure safe transfusions, while **Roche Diagnostics** is rolling out new assays to improve screening processes. 

Notably, **Cerus Corporation** has expanded its user base for the INTERCEPT Blood System, which is gaining traction for pathogen inactivation protocols. In terms of mergers and acquisitions, **Abbott Laboratories** announced their acquisition of **St. Jude Medical** in **January 2017**, aiming to bolster capabilities in cardiac and vascular devices, directly impacting diagnostic segments. The growth of this sector has been robust, with estimated market valuations exceeding **USD 3 billion** as of **2023**, driven by increasing demand for safer blood transfusions and technological innovations. 

Moreover, the ongoing focus on regulatory compliance and safety standards by organizations such as the **Food and Drug Administration** is shaping the industry's landscape. Over the past two years, the adoption of automated systems and AI-based diagnostics has gained momentum, reflecting a shift towards efficiency and accuracy in blood transfusion practices in the US.

## **US Blood Transfusion Diagnostics Market Segmentation Insights**

### **Blood Transfusion Diagnostics Market Product Type Outlook**

### **Blood Transfusion Diagnostics Market Technique Outlook**

### **Blood Transfusion Diagnostics Market End User Outlook**

### **Blood Transfusion Diagnostics Market Application Outlook**

## Market Drivers

### Growing Awareness of Blood Safety

There is a heightened awareness regarding blood safety and the risks associated with transfusions, which significantly impacts the blood transfusion-diagnostics market. Educational campaigns and initiatives by health organizations emphasize the importance of rigorous testing and screening of blood products. This awareness drives healthcare providers to adopt more comprehensive diagnostic measures to ensure the safety of transfusions. As a result, the market is expected to see an increase in demand for diagnostic tools that can detect infectious diseases and other potential risks in blood products, thereby enhancing patient safety and trust in transfusion practices.

### Rising Prevalence of Blood Disorders

The increasing incidence of blood disorders such as anemia, hemophilia, and thalassemia is a crucial driver for the blood transfusion-diagnostics market. As more individuals are diagnosed with these conditions, the demand for accurate diagnostic tools and blood products rises. According to recent data, approximately 3 million Americans are affected by anemia alone, necessitating regular blood transfusions and monitoring. This trend indicates a growing need for advanced diagnostic solutions that can ensure safe and effective blood transfusions. The blood transfusion-diagnostics market is likely to expand. This expansion is due to healthcare providers seeking to improve patient outcomes through better diagnostic capabilities.

### Regulatory Changes and Quality Standards

Regulatory changes and the establishment of stringent quality standards are shaping the blood transfusion-diagnostics market. Agencies such as the FDA enforce regulations that require rigorous testing and validation of blood products and diagnostic tools. Compliance with these regulations is essential for manufacturers and healthcare providers, as it ensures the safety and efficacy of blood transfusions. The ongoing evolution of these regulations may lead to increased investments in research and development of new diagnostic technologies. Consequently, the blood transfusion-diagnostics market is likely to experience growth as stakeholders adapt to these regulatory demands and strive to meet high-quality standards.

### Technological Innovations in Diagnostics

Technological advancements in diagnostic tools are transforming the blood transfusion-diagnostics market. Innovations such as automated blood typing systems, molecular diagnostics, and point-of-care testing devices enhance the accuracy and speed of blood testing. For instance, the introduction of next-generation sequencing technologies allows for more precise identification of blood group antigens, which is critical for safe transfusions. The market is projected to grow as these technologies become more integrated into clinical practice, potentially increasing efficiency and reducing the risk of transfusion-related complications. As a result, healthcare facilities are likely to invest in these advanced diagnostic solutions.

### Aging Population and Increased Surgical Procedures

The aging population in the United States is contributing to a higher demand for surgical procedures, which in turn drives the blood transfusion-diagnostics market. Older adults are more likely to undergo surgeries that require blood transfusions, such as orthopedic and cardiac procedures. As the population aged 65 and older continues to grow, the need for effective blood management and diagnostic solutions becomes increasingly critical. This demographic shift suggests that healthcare systems will need to enhance their blood transfusion protocols and diagnostic capabilities to accommodate the rising number of surgical interventions, thereby expanding the market.

## Future Outlook

The [Blood Transfusion Diagnostics Market](https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market-1126) is projected to grow at a 5.89% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for blood products, and regulatory support.

**New opportunities:**

- Development of AI-driven blood screening technologies Expansion of mobile blood collection units Integration of blockchain for blood traceability

By 2035, the market is expected to achieve robust growth, driven by innovation and strategic investments.

## Segment Insights

### By Product Type: Infectious Disease Testing (Largest) vs. Blood Grouping Tests (Fastest-Growing)

The US blood transfusion-diagnostics market is characterized by a robust distribution of market share across various product types. Infectious Disease Testing holds the largest share, driven by stringent regulations and increasing incidences of transfusion-transmitted infections. Blood Grouping Tests, while smaller in share, have shown rapid adoption, particularly with advancements in technology enhancing accuracy and reducing turnaround times.

Growth trends in this segment are being fueled by technological innovations and an increasing demand for safe blood transfusion practices. The emergence of new testing methodologies and the rising awareness of transfusion safety are key drivers. Compatibility Testing and Nucleic Acid Testing are also gaining traction, reflecting the industry's response to evolving healthcare needs and the urgency for precise diagnostics.

Testing: Infectious Disease (Dominant) vs. Blood Grouping (Emerging)

Infectious Disease Testing is the dominant segment, primarily because it addresses critical safety issues within blood transfusions, ensuring the detection of pathogens. This segment is heavily regulated to minimize risks associated with transfusion-transmitted infections. On the other hand, Blood Grouping Tests are emerging as a vital part of pre-transfusion screening, leveraging recent advancements in blood grouping technologies that enhance efficiency and reliability. While Infectious Disease Testing is pivotal for public safety, Blood Grouping Tests are rapidly evolving, incorporating automation and more accurate techniques to accommodate the growing demand for transfusions in a diverse patient population.

### By Technique: Enzyme-Linked Immunosorbent Assay (Largest) vs. Polymerase Chain Reaction (Fastest-Growing)

The US blood transfusion-diagnostics market exhibits a diverse distribution of techniques, with Enzyme-Linked Immunosorbent Assay (ELISA) capturing the largest share due to its reliability and established usage in various applications. Polymerase Chain Reaction (PCR), while smaller in market share, is rapidly gaining traction owing to its high sensitivity and specificity for detecting pathogens, making it almost indispensable in modern diagnostics.

Growth trends are being driven by advancements in technology, increasing demand for accurate and rapid diagnostics, and a rising prevalence of chronic diseases that necessitate frequent blood testing and transfusion practices. Moreover, the ongoing need for safety and precision in blood transfusions is pushing healthcare providers to adopt more innovative diagnostic techniques, particularly PCR, which is considered the fastest-growing method in this space.

Technique: ELISA (Dominant) vs. PCR (Emerging)

Enzyme-Linked Immunosorbent Assay (ELISA) stands as the dominant technique in the segment due to its high throughput, cost-effectiveness, and versatility in detecting a wide range of antigens and antibodies. Commonly used for screening blood donors and various diseases, it has a robust market presence. Conversely, Polymerase Chain Reaction (PCR) is emerging as a critical technique owing to its ability to amplify DNA, thus providing precise detection of infectious agents. This method's quick turnaround time and accuracy significantly enhance diagnostic capabilities in transfusion diagnostics. The differentiation between these techniques highlights the shift towards more advanced and rapid testing methodologies, with PCR positioned to capture greater market share in the coming years.

### By End User: Hospitals (Largest) vs. Blood Banks (Fastest-Growing)

In the US blood transfusion-diagnostics market, hospitals constitute the largest segment, driven by the high volume of blood transfusions performed daily. Blood banks follow closely, serving as critical hubs for blood collection and distribution, reflecting significant market share but slightly lesser compared to hospitals. Diagnostic laboratories and academic institutions hold smaller shares, primarily supporting research and specialized testing needs within the healthcare ecosystem.

The growth trends within this segment indicate a robust demand for blood transfusion services and diagnostic solutions, largely influenced by an increase in surgical procedures and emergency care requirements. Additionally, the expansion of blood banks as the fastest-growing segment is attributed to initiatives for enhancing blood donation and advancements in storage technologies, enhancing operational efficiency and patient care quality in the US blood transfusion-diagnostics market.

Hospitals (Dominant) vs. Blood Banks (Emerging)

Hospitals represent the dominant force in the US blood transfusion-diagnostics market due to their integral role in patient care, conducting numerous transfusions across various departments including emergency and surgical units. Their extensive network and resources place them at the forefront of service delivery in this sector. Conversely, blood banks, while emerging, are increasingly recognized for their vital function in blood collection, testing, and distribution. They are adapting to technological advancements and increasing demand for blood products, thus carving a prominent niche within the market. Both segments are crucial for ensuring seamless availability and safety of blood supplies, underscoring their interdependent roles in the healthcare landscape.

### By Application: Transfusion Medicine (Largest) vs. Organ Transplantation (Fastest-Growing)

The US blood transfusion-diagnostics market exhibits a diverse distribution among its application segments, with Transfusion Medicine holding the largest market share. This segment plays a crucial role in routine and emergency transfusion practices, making it indispensable. Organ Transplantation, while possessing a smaller market share, is experiencing rapid growth due to increasing organ donation rates and advances in transplant procedures, indicating a shift in focus within the healthcare system.

Growth trends in the US blood transfusion-diagnostics market highlight a growing demand for advanced diagnostic solutions, particularly in the Organ Transplantation segment. Factors such as an aging population, rising prevalence of chronic diseases, and technological advancements in transfusion technology are the primary drivers of this growth. Moreover, ongoing research in the field of transfusion medicine is paving the way for innovative products, further stimulating market expansion in the near future.

Transfusion Medicine (Dominant) vs. Clinical Research (Emerging)

Transfusion Medicine is established as the dominant segment within the US blood transfusion-diagnostics market, characterized by its extensive use in hospitals and emergency care settings. It focuses on ensuring the safe and efficient transfusion of blood products, with stringent regulatory standards governing the process. Conversely, Clinical Research is considered an emerging segment, focused on exploring novel therapies and technologies related to blood transfusion and diagnostics. As pharmaceutical and biotech companies continue to invest in research, this segment is witnessing growth driven by the need for innovative diagnostic solutions and therapies, which ultimately complements the advancements seen in Transfusion Medicine.

## Competitive Benchmarking

The blood transfusion-diagnostics market is characterized by a dynamic competitive landscape. This landscape is driven by technological advancements, regulatory changes, and an increasing demand for safe blood products. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Grifols (ES) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Abbott Laboratories (US) focuses on expanding its diagnostic portfolio through strategic acquisitions and collaborations, while Roche Diagnostics (CH) emphasizes research and development to introduce cutting-edge solutions. Grifols (ES) is actively pursuing global expansion, particularly in emerging markets, to capitalize on the growing need for transfusion diagnostics.The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This competitive structure allows for a diverse range of products and services, catering to various customer needs while fostering innovation across the sector.
In October Abbott Laboratories (US) announced the launch of a new rapid blood screening test designed to detect infectious diseases in blood donations. This strategic move is significant as it not only enhances the safety of blood transfusions but also positions Abbott as a leader in the diagnostic space, potentially increasing its market share. The introduction of such innovative solutions is likely to set new standards in the industry, compelling competitors to elevate their offerings.
In September Roche Diagnostics (CH) unveiled a digital platform aimed at streamlining blood transfusion processes through enhanced data analytics. This initiative underscores Roche's commitment to digital transformation, which is increasingly vital in the diagnostics market. By integrating advanced analytics, Roche aims to improve operational efficiencies and patient outcomes, thereby reinforcing its competitive edge.
In August Grifols (ES) entered into a partnership with a leading biotechnology firm to develop next-generation blood screening technologies. This collaboration is pivotal as it not only expands Grifols' technological capabilities but also enhances its product offerings in the transfusion diagnostics market. Such strategic alliances are becoming essential for companies seeking to innovate and maintain relevance in a rapidly evolving landscape.
As of November current trends in the blood transfusion-diagnostics market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet the growing demands of the healthcare sector.

## Recent News & Developments

In recent months, the US Blood Transfusion Diagnostics Market has seen significant developments among key players. **Siemens Healthineers** continues to innovate with their high-performance analyzers, enhancing transfusion compatibility testing. **Mayo Clinic Laboratories** is advancing in genetic testing to ensure safe transfusions, while **Roche Diagnostics** is rolling out new assays to improve screening processes. 

Notably, **Cerus Corporation** has expanded its user base for the INTERCEPT Blood System, which is gaining traction for pathogen inactivation protocols. In terms of mergers and acquisitions, **Abbott Laboratories** announced their acquisition of **St. Jude Medical** in **January 2017**, aiming to bolster capabilities in cardiac and vascular devices, directly impacting diagnostic segments. The growth of this sector has been robust, with estimated market valuations exceeding **USD 3 billion** as of **2023**, driven by increasing demand for safer blood transfusions and technological innovations. 

Moreover, the ongoing focus on regulatory compliance and safety standards by organizations such as the **Food and Drug Administration** is shaping the industry's landscape. Over the past two years, the adoption of automated systems and AI-based diagnostics has gained momentum, reflecting a shift towards efficiency and accuracy in blood transfusion practices in the US.

## Report Scope

| MARKET SIZE 2024 | 2295.16(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2430.34(USD Million) |
| MARKET SIZE 2035 | 4308.57(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Grifols (ES), Terumo Corporation (JP), Baxter International (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Hologic (US) |
| Segments Covered | Product Type, Technique, End User, Application |
| Key Market Opportunities | Integration of advanced molecular diagnostics enhances safety and efficiency in the blood transfusion-diagnostics market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in blood transfusion-diagnostics, enhancing safety and efficiency. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US blood transfusion-diagnostics market in 2024?**
A: The market valuation was $2295.16 Million in 2024.

**Q: What is the projected market valuation for the US blood transfusion-diagnostics market by 2035?**
A: The projected valuation for 2035 is $4308.57 Million.

**Q: What is the expected CAGR for the US blood transfusion-diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.89% during the forecast period 2025 - 2035.

**Q: Which product type segment had the highest valuation in 2024?**
A: The Compatibility Testing segment had the highest valuation at $700.0 Million in 2024.

**Q: What are the projected values for the Blood Grouping Tests segment by 2035?**
A: The projected values for the Blood Grouping Tests segment are expected to reach $1100.0 Million by 2035.

**Q: Which technique segment is anticipated to show the most growth by 2035?**
A: The Chemiluminescent Immunoassay segment is anticipated to show significant growth, reaching $1200.0 Million by 2035.

**Q: What was the valuation of the Diagnostic Laboratories segment in 2024?**
A: The valuation of the Diagnostic Laboratories segment was $500.0 Million in 2024.

**Q: Which end user segment is projected to have the highest valuation by 2035?**
A: The Hospitals segment is projected to have the highest valuation at $2000.0 Million by 2035.

**Q: What is the expected growth for the Transfusion Medicine application segment by 2035?**
A: The Transfusion Medicine application segment is expected to grow to $2200.0 Million by 2035.

**Q: Who are the key players in the US blood transfusion-diagnostics market?**
A: Key players include Roche Diagnostics, Abbott Laboratories, Grifols, Terumo Corporation, Baxter International, Ortho Clinical Diagnostics, Bio-Rad Laboratories, and Hologic.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-blood-transfusion-diagnostics-market-18690*